Table 2. Demographics of patients with recurrent ICI-related ILD (n=8).

Clinical features	ILD recurrence (N=8)
Duration of systemic cancer therapy, days [range]	5 [1–183]
Treatment cycles, median [range]	1 [1–14]
Grade of ILD, n [%]
1	1 [11]
2	6 [67]
3	1 [11]
4	1 [11]
5	0
Systemic steroid therapy, n [%]
mPSL pulse	4 [44]
PSL ≥30 mg/day	3 [33]
PSL <30 mg/day	2 [22]

ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; PSL, prednisolone; mPSL, methylprednisolone.